Announced Wed, 24 Sept · 17:39 IST

In compliance with the provisions of Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, a summary of the proceedings of the 29th AGM of the Company held on ....

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Chemo Pharma Laboratories Ltd held its 83rd Annual General Meeting on September 24, 2025, via video conferencing from 4:00 PM to 4:30 PM, with the required quorum present. Eleven resolutions were placed before shareholders, including adoption of FY25 audited financial statements and appointment/regularization of Mr. Ruchit Mehta as MD & CEO, Mr. Utsav Trivedi as Executive Director & CFO, and three independent directors. A key special resolution seeks to change the company's name to 'Starsource Multitrade Limited' and alter the object clause to venture into trading of goods and commodities on retail and wholesale basis, reflecting a strategic pivot by the new management that took over post Open Offer. M/s SSRV & Associates were appointed as new statutory auditors to fill the casual vacancy left by Sanjay Rane & Associates LLP, and outgoing promoter Shanta Sornani was reclassified from 'Promoter Group' to 'Public' shareholder. Voting results from remote e-voting and e-voting at the AGM are awaited and will be declared based on the scrutinizer's report.

Likely market impact

The proposed name change and object clause alteration signal a major business pivot from pharmaceuticals to a multi-commodity trading company under new management, which could materially reshape the company's future revenue mix and investor appeal. Shareholders should monitor the voting outcome on these special resolutions as they will redefine the company's identity and business direction.